NovaBay Pharmaceuticals, Inc.

NYSEAM:NBY Stock Report

Market Cap: US$2.6m

NovaBay Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Justin Hall

Chief executive officer

US$364.1k

Total compensation

CEO salary percentage96.1%
CEO tenure9yrs
CEO ownership0.001%
Management average tenureno data
Board average tenure4.2yrs

Recent management updates

Recent updates

We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

Mar 29
We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Justin Hall's remuneration changed compared to NovaBay Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$364kUS$350k

-US$17m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$365kUS$350k

-US$16m

Sep 30 2022n/an/a

-US$9m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$5m

Dec 31 2021US$796kUS$329k

-US$7m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$747kUS$286k

-US$11m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$326kUS$260k

-US$10m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018US$572kUS$260k

-US$7m

Sep 30 2018n/an/a

-US$4m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$6m

Dec 31 2017US$665kUS$228k

-US$7m

Compensation vs Market: Justin's total compensation ($USD364.15K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Justin's compensation has been consistent with company performance over the past year.


CEO

Justin Hall (46 yo)

9yrs

Tenure

US$364,146

Compensation

Mr. Justin M. Hall, Esq. has been General Counsel at NovaBay Pharmaceuticals, Inc. since December 2015, Corporate Secretary since July 16, 2017 and President and Chief Executive Officer since June 17, 2019...


Board Members

NamePositionTenureCompensationOwnership
Justin Hall
President4.3yrsUS$364.15k0.0014%
$ 36.0
Paul Freiman
Independent Chairman22.6yrsUS$78.08k0.0016%
$ 40.9
Yenyou Zheng
Independent Director5.3yrsUS$74.08k0.0015%
$ 39.9
Mijia Wu
Director8.9yrsUS$40.58k0.0015%
$ 39.9
Pedram Hamrah
Member of Ophthalmic Advisory Board9.2yrsno datano data
Swan Sit
Independent Director5yrsUS$59.08k0.0015%
$ 39.9
Komal Thakore
Member of the Optometry Advisory Board4.1yrsno datano data
Amr Kouchouk
Member of the Ophthalmic Advisory Board4.1yrsno datano data
John Aljian
Member of the Ophthalmic Advisory Board4.1yrsno datano data
Laura Periman
Member of the Ophthalmic Advisory Board4.1yrsno datano data
Milap Mehta
Member of the Ophthalmic Advisory Board4.1yrsno datano data
Melanie Bennett-Sims
Member of the Ophthalmic Advisory Board4.1yrsno datano data

4.2yrs

Average Tenure

50yo

Average Age

Experienced Board: NBY's board of directors are considered experienced (4.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NovaBay Pharmaceuticals, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Stephen DunnDawson James Securities
Pooya HemamiDesjardins Securities Inc.